Is Spruce Biosciences Inc (SPRB) overvalued? · rev $4.9M
Spruce Biosciences Inc (SPRB) is a biotechnology company listed on US.
This page asks whether Spruce Biosciences Inc (SPRB) looks expensive on cached numbers — not a short thesis.
Latest reported SPRB revenue for 2024-12-31 was $4.9M. Net income was -$53.0M. Revenue was down 51.3% from 2023-12-31 to 2024-12-31. SPRB currently screens at market cap $3.0M.
SPRB currently screens at market cap $3.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SPRB 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SPRB stock page for the full model, not this heading.
Not investment advice.